Cigna Investments Inc. New decreased its stake in Cooper Companies, Inc. (The) (NYSE:COO) by 3.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,998 shares of the medical device company’s stock after selling 61 shares during the period. Cigna Investments Inc. New’s holdings in Cooper Companies, Inc. (The) were worth $478,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. YorkBridge Wealth Partners LLC raised its stake in shares of Cooper Companies, Inc. (The) by 18.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 520 shares of the medical device company’s stock valued at $105,000 after buying an additional 81 shares during the period. Archford Capital Strategies LLC increased its position in Cooper Companies, Inc. (The) by 116.7% in the first quarter. Archford Capital Strategies LLC now owns 674 shares of the medical device company’s stock valued at $135,000 after buying an additional 363 shares in the last quarter. Penserra Capital Management LLC increased its position in Cooper Companies, Inc. (The) by 9.5% in the first quarter. Penserra Capital Management LLC now owns 782 shares of the medical device company’s stock valued at $156,000 after buying an additional 68 shares in the last quarter. Pacer Advisors Inc. increased its position in Cooper Companies, Inc. (The) by 3.8% in the first quarter. Pacer Advisors Inc. now owns 848 shares of the medical device company’s stock valued at $170,000 after buying an additional 31 shares in the last quarter. Finally, Visionary Asset Management Inc. bought a new position in Cooper Companies, Inc. (The) during the second quarter valued at approximately $201,000. 98.06% of the stock is owned by hedge funds and other institutional investors.
Cooper Companies, Inc. (COO) opened at 244.57 on Thursday. The company’s 50-day moving average price is $244.98 and its 200-day moving average price is $216.48. The stock has a market cap of $11.95 billion, a P/E ratio of 36.67 and a beta of 0.61. Cooper Companies, Inc. has a one year low of $158.73 and a one year high of $256.39.
Cooper Companies, Inc. (The) (NYSE:COO) last announced its quarterly earnings results on Thursday, June 1st. The medical device company reported $2.50 EPS for the quarter, beating the Zacks’ consensus estimate of $2.25 by $0.25. Cooper Companies, Inc. (The) had a net margin of 16.02% and a return on equity of 15.88%. The firm had revenue of $522.40 million during the quarter, compared to the consensus estimate of $520.71 million. During the same quarter last year, the firm earned $2.05 EPS. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year. Analysts forecast that Cooper Companies, Inc. will post $9.63 EPS for the current fiscal year.
The company also recently disclosed a semiannual dividend, which was paid on Monday, August 7th. Investors of record on Friday, July 21st were given a $0.03 dividend. This represents a yield of 0.02%. The ex-dividend date was Wednesday, July 19th. Cooper Companies, Inc. (The)’s dividend payout ratio (DPR) is currently 0.90%.
Several research analysts have recently commented on the company. Oppenheimer Holdings, Inc. set a $225.00 price objective on Cooper Companies, Inc. (The) and gave the stock a “hold” rating in a report on Saturday, June 3rd. BidaskClub downgraded Cooper Companies, Inc. (The) from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research downgraded Cooper Companies, Inc. (The) from a “buy” rating to a “hold” rating in a report on Monday. Robert W. Baird lifted their price objective on Cooper Companies, Inc. (The) from $239.00 to $251.00 and gave the stock an “outperform” rating in a report on Thursday, July 6th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating and issued a $206.00 price objective (up previously from $200.00) on shares of Cooper Companies, Inc. (The) in a report on Monday, June 5th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $242.00.
In related news, EVP Carol R. Kaufman sold 44,092 shares of the stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $242.81, for a total value of $10,705,978.52. Following the sale, the executive vice president now directly owns 60,419 shares of the company’s stock, valued at approximately $14,670,337.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Randal Golden sold 1,621 shares of the stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $243.65, for a total transaction of $394,956.65. Following the completion of the sale, the vice president now directly owns 1,731 shares in the company, valued at $421,758.15. The disclosure for this sale can be found here. Insiders sold a total of 67,331 shares of company stock worth $16,400,454 over the last three months. 1.60% of the stock is currently owned by corporate insiders.
About Cooper Companies, Inc. (The)
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.
